pegcetacoplan (Empaveli) Report issue

Biologics Peptide Orphan Drug FDA Approved FDA First in Class Fast Track FDA Priority Review FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

apl-2

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (1)


 

Hemoglobinuria, Paroxysmal (approved 2021)

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Anemia, Hemolytic, Autoimmune (Phase 3)

Dichlorodiphenyldichloroethane (Phase 3)

Drugs, Investigational (Phase 3)

Fallopian Tube Neoplasms (Phase 2)

Genetic Diseases, Inborn (Phase 3)

Geographic Atrophy (Phase 3)

Glomerulonephritis (Phase 3)

Glomerulonephritis, IGA (Phase 2)

Glomerulonephritis, Membranoproliferative (Phase 3)

Glomerulonephritis, Membranous (Phase 2)

Hamartoma (Phase 2)

Hemoglobinuria, Paroxysmal (Phase 3)

Immune System Diseases (Phase 3)

Kidney Diseases (Phase 3)

Kidney Transplantation (Phase 2)

Lupus Nephritis (Phase 2)

Macular Degeneration (Phase 3)

Motor Neuron Disease (Phase 2)

Ovarian Diseases (Phase 2)

Ovarian Neoplasms (Phase 2)

Thrombosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue